Atrial fibrillation, even in the absence of rheumatic valvular disease, predisposes patients to
embolic complications, but the role of antithrombotic therapy in the prevention of such …

BACKGROUNDAtrial fibrillation in the absence of rheumatic valvular disease is associated
with a fivefold to sevenfold increased risk of ischemic stroke. METHODS AND MAIN …

Abstract From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic
atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin …

Recent randomized trials have consistently demonstrated the marked efficacy of warfarin in
reducing the risk of stroke caused by nonrheumatic atrial fibrillation. These trials have …

ContextAtrial fibrillation, a common disorder that affects nearly one sixth of the population
aged 75 years and older, is a major risk factor for stroke. ObjectivesTo review and evaluate …

OBJECTIVE: Appropriate use of drugs to prevent thromboembolism in patients with atrial
fibrillation (AF) involves comparing the patient's risk of stroke and risk of hemorrhage. This …

Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial
fibrillation, but the value of this agent relative to aspirin is unclear. In the first Stroke …

There new studies help clarify important clinical issues regarding antithrombotic therapy for
stroke prevention in patients with atrial fibrillation. The European Atrial Fibrillation Trial …

Atrial fibrillation is associated with a sixfold increased risk for stroke. More than a dozen
published randomized trials of anticoagulants or antiplatelet agents for stroke prevention …

There is a demonstrated statistical association between atrial fibrillation, rheumatic valvular
disease, and embolic stroke. This article assesses the results of 6 major clinical trials …